Harpreet S. Dhaliwal
Known title: SVP Cml Mfg & Supply ChainCIK: 0001886794
Associated companies
Transaction History
| PCVX | ▼ Sell | Tax Withholding | 7,651 | $462K | 9/8/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 659 | $41K | 9/2/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 361 | $22K | 8/31/2026 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 17,000 | $421K | 8/5/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 17,000 | $935K | 8/5/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 604 | $36K | 3/9/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 465 | $29K | 3/2/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 292 | $18K | 2/28/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 53,409 | $0 | 2/26/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 9,743 | $455K | 12/31/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 1,204 | $39K | 9/8/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 291 | $9K | 9/2/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 783 | $25K | 9/2/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 464 | $15K | 9/2/2025 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 3,990 | $100K | 12/28/2022 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 1,513 | $40K | 9/2/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 17,500 | $0 | 3/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.